Binance revamps Launchpool, streamlines the BNB experience

By reducing friction on Launchpool participation and BNB benefits, Binance aims to create a smoother experience for both new and seasoned crypto participants.
Last year, nearly 19 out of every 20 dollars in exchange-hosted airdrops flowed through global crypto exchange Binance — 94% of the $2.7 billion total, according to CoinMarketCap. Much of that windfall reached BNB holders, who tapped 21 Launchpool campaigns worth $1.75 billion without paying trading fees or leaving the app.
Now Binance is tightening the feedback loop even further: a rebuilt Launchpool dashboard and an all-in-one BNB utility page bring staking, real-time rewards and historical yield data under one tap.
For users, the update turns what was once a multi-tab treasure hunt into a single screen; for Binance, it reinforces the exchange's formula of high-quality listings (a 0 % delisting rate on 77 tokens) matched with friction-free access to fresh incentives.
Hassle-free staking and airdrops
Launchpool events on Binance have long been a draw for those seeking direct exposure to emerging projects. Throughout 2024, the exchange hosted 21 Launchpool events, distributing over $1.75 billion in tokens.
However, for many participants, the process of staking BNB, keeping track of allocation, and then hunting down claim periods could feel disjointed. The reworked Launchpool interface aims to change that by centralizing these steps under one streamlined dashboard, with integrated support for BNB staking, airdrop monitoring and push notifications for upcoming or expiring pools.
Now, participants can subscribe to BNB Simple Earn products directly from the Launchpool page, seeing real-time token airdrop allocations and locked BNB positions in a single view. The design also adds a quick-start FAQ and improved navigation, leaning on the idea that many users prefer in-app prompts over sifting through external resources.
BNB at the center
BNB plays a central role in Binance's reward ecosystem, serving as the key asset for participating in Launchpool, Megadrop, and HODLer airdrops. For users looking to access these opportunities, holding BNB is the entry point.
The redesign of the dedicated BNB utility page consolidates each token's various perks — from trading fee discounts and VIP privileges to real-time airdrop opportunities. BNB functions as a gateway to new listings, reduced fees and exclusive promotions, like participation in events like Launchpool, Megadrop and HODLer Airdrops. Users holding BNB can combine price appreciation with additional rewards from these ecosystem programs.
Rather than scattering these details across multiple sections, the updated page lays out how BNB interacts with each program, offers a look at past distributions and highlights ongoing reward opportunities. Interested parties can see more details about the token's performance metrics and utility in Binance's internal analysis article, 'BNB: The Utility Token That Pays to Hold.'
Binance in numbers
These changes also arrive amid Binance's impressive track record in token distribution and listing standards. According to CoinMarketCap's recent report 'Examining Token Listings on CEXes,' Binance leads the airdrop scene, accounting for 94% of the total $2.7 billion in launchpool and airdrop rewards distributed across exchanges.
In 2024, Binance rewarded $2.6 billion to its users, underlining its prominent presence in the space. The same report notes that Binance's listing standards maintain a 0% delisting rate for all 77 tokens listed in 2023 and 2024, reflecting a commitment to quality that helps reduce investor risk.
By combining a proven track record in token distribution with more intuitive navigation, Binance showcases how removing barriers ultimately encourages deeper participation and signals where the broader market is headed next.
Source: https://cointelegraph.com/news/binance-revamps-launchpool-streamlines-the-bnb-experience

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Globe and Mail

13-06-2025

• Globe and Mail

NSCLC Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 10+ Companies and 10+ Therapies

DelveInsight's, 'Non-Small-Cell Lung Cancer Pipeline Insight 2025' report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Non-Small-Cell Lung cancer (NSCLC) pipeline landscape. It covers the NSCLC pipeline drug profiles, including clinical and nonclinical stage products. It also covers the NSCLC pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight and stay ahead in understanding the NSCLC Treatment Landscape. Click here to read more @ NSCLC Pipeline Outlook Key Takeaways from the NSCLC Pipeline Report In June 2025, Revolution Medicines Inc. announced a study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to docetaxel. This is a global, randomized, open-label, Phase 3 study designed to evaluate whether treatment with daraxonrasib will improve progression free survival (PFS) or overall survival (OS) compared to docetaxel chemotherapy in patients with NSCLC who were previously treated. Patients will be randomized in a 1:1 ratio to receive daraxonrasib or docetaxel chemotherapy. In June 2025, Amgen conducted a study is to characterize safety and efficacy of 2 dose levels of AMG 193 by investigator, and to evaluate AMG 193 monotherapy efficacy by Blinded Independent Central Review (BICR). In June 2025, Allist Pharmaceuticals Inc. organized a Phase 3 clinical study to assess the efficacy and safety of adjuvant treatment with firmonertinib versus placebo in participants with Stage IB-IIIB NSCLC with uncommon EGFR mutations (exon 20 insertions, PACC and classical-like mutations) after complete surgical resection with or without adjuvant chemotherapy. In June 2025, AstraZeneca announced a Phase III study to determine the efficacy and safety of durvalumab + tremelimumab combination therapy versus platinum-based SoC chemotherapy in the first-line treatment of patients with epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) wild-type advanced or metastatic NSCLC. DelveInsight's NSCLC pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for NSCLC treatment. The leading NSCLC Companies such as GlaxoSmithKline, Novartis, AstraZeneca, Eli Lilly and Company, Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck, Millennium Pharmaceuticals, Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Bristol Myers Squibb, and Sanofi are actively involved in research and development. Additionally, innovative biotechs like IO Biotech, Transgene, Immutep S.A., Daiichi Sankyo, Inc., Regeneron Pharmaceuticals, Hanmi Pharmaceutical Company Limited, TYK Medicines, Inc. and others. Promising NSCLC Pipeline Therapies such as Brigatinib, Tyrosine kinase inhibitor, sintilimab combined with anlotinib, Osimertinib, Gefitinib, SSGJ-707, Vandetanib, Atezolizumab, Tiragolumab and others. Stay informed about the cutting-edge advancements in NSCLC treatments. Download for updates and be a part of the revolution in cancer care @ NSCLC Clinical Trials Assessment NSCLC Emerging Drugs Profile AMG 510: Amgen AMG 510 is being developed by Amgen. Phase 1 clinical trials were completed in late 2020. Because the G12C KRAS mutation is relatively common in some cancer types, 14% of non-small-cell lung cancer adenocancer patients and 5% of colorectal cancer patients, and AMG 510 is the first drug candidate to target this mutation, there have been high expectations for the drug. The Food and Drug Administration has granted a fast track designation to AMG 510 for the treatment of metastatic non-small-cell lung cancer with the G12C KRAS mutation. The drug is in preregistration stage for the treatment of NSCLC. CMP 001: Cytos Biotechnology CMP 001 is a short piece of DNA, called an oligonucleotide that Checkmate designed to mimic the DNA of bacteria. It encapsulated the DNA in noninfectious virus-like particles, or VLPs. The company created CMP-001 to be administered directly to a tumor. When this occurs, the immune system sees VLPs as foreign. It generates immune cells called antigen presenting cells that release the DNA from the VLPs. CMP 001 is in phase 1 of clinical trials for the treatment of non-small cell lung cancer. The NSCLC Pipeline Report Provides Insights into The report provides detailed insights about companies that are developing therapies for the treatment of NSCLC with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for NSCLC Treatment. NSCLC Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. NSCLC Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different NSCLC mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the NSCLC market Learn more about NSCLC Drugs opportunities in our groundbreaking NSCLC research and development projects @ NSCLC Unmet Needs NSCLC Companies GlaxoSmithKline, Novartis, AstraZeneca, Eli Lilly and Company, Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck, Millennium Pharmaceuticals, Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Bristol Myers Squibb, and Sanofi are actively involved in research and development. Additionally, innovative biotechs like IO Biotech, Transgene, Immutep S.A., Daiichi Sankyo, Inc., Regeneron Pharmaceuticals, Hanmi Pharmaceutical Company Limited, TYK Medicines, Inc. and others. Non-Small-Cell Lung cancer (NSCLC) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Subcutaneous Intravenous Oral Parenteral Intramuscular Molecule Type NSCLC Products have been categorized under various Molecule types such as Small molecules Peptides Polymer Gene Therapy Monoclonal antibodies Product Type Discover the latest advancements in NSCLC treatment by visiting our website. Stay informed about how we're transforming the future of neurology @ NSCLC Market Drivers and Barriers, and Future Perspectives Scope of the NSCLC Pipeline Report Coverage- Global NSCLC Companies- GlaxoSmithKline, Novartis, AstraZeneca, Eli Lilly and Company, Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck, Millennium Pharmaceuticals, Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Bristol Myers Squibb, and Sanofi are actively involved in research and development. Additionally, innovative biotechs like IO Biotech, Transgene, Immutep S.A., Daiichi Sankyo, Inc., Regeneron Pharmaceuticals, Hanmi Pharmaceutical Company Limited, TYK Medicines, Inc. and others. NSCLC Pipeline Therapies- Brigatinib, Tyrosine kinase inhibitor, sintilimab combined with anlotinib, Osimertinib, Gefitinib, SSGJ-707, Vandetanib, Atezolizumab, Tiragolumab and others. NSCLC Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination NSCLC Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III For a detailed overview of our latest research findings and future plans, read the full details of NSCLC Pipeline on our website @ NSCLC Emerging Drugs and Companies Table of Contents Introduction Executive Summary Non-Small-Cell Lung cancer (NSCLC): Overview Pipeline Therapeutics Therapeutic Assessment Non-Small-Cell Lung cancer (NSCLC) – DelveInsight's Analytical Perspective In-depth Commercial Assessment Late Stage Products (Pre Registration) AMG 510: Amgen Drug profiles in the detailed report….. Mid Stage Products (Phase II) Drug Name: Company Name Drug profiles in the detailed report….. Early Stage Products (Phase I) CMP 001: Cytos Biotechnology Inactive Products Non-Small-Cell Lung cancer (NSCLC) Key Companies Non-Small-Cell Lung cancer (NSCLC) Key Products Non-Small-Cell Lung cancer (NSCLC)- Unmet Needs Non-Small-Cell Lung cancer (NSCLC)- Market Drivers and Barriers Non-Small-Cell Lung cancer (NSCLC)- Future Perspectives and Conclusion Non-Small-Cell Lung cancer (NSCLC) Analyst Views Non-Small-Cell Lung cancer (NSCLC) Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:

Fast Company

13-06-2025

• Fast Company

Spot the scam: How to outsmart online cons like a pro

With any innovation comes risk, but those risks can be managed with the right precautions. Protecting yourself online is just as important in your crypto wallet as it is in your email inbox or your banking app. According to the largest ever study of crypto holders in America, which my organization conducted, just 3% reported negative experiences with crypto, and of these, less than a third had experienced fraud or security breaches personally. That's less than 1% total. Compare that to traditional banking scams, where 34% of U.S. adults have experienced in the last year, or online dating, where 40% of users have reported being targeted by scams. The point is that scams happen in every corner of the internet. The good news? The habits that keep you safe in other online spaces also work in Web3. Find the scams before they find you Scams can happen to anyone, anywhere—no matter how smart or tech savvy you may be. By staying alert, you can avoid the hassle and heartache that comes with being swindled. These are some of the most common tactics used by online scammers: Pig butchering: Scammers build fake relationships online—posing as a friend, love interest, or mentor—before persuading you to invest in a 'can't miss' opportunity. Once the crypto or money is sent, the scammers vanish. Pump and dump: A lesser-known token gets hyped up by influencers or group chats, driving up demand. The scam organizers then sell their holdings at the top—leaving latecomers holding the bag. Fake giveaways: Look out for messages claiming you'll receive free crypto if you send a little first. No legitimate organization or person asks you to pay in order to receive a giveaway. Impersonation scams: Fraudsters pretend to be customer service reps, government agencies, or wallet providers to get you to send funds or hand over your login details. Phishing attacks: These often come through fake emails or links on social media, asking you to log in or verify your wallet. The goal? Steal your private keys or seed phrases. Stay safe with smart internet habits Online safety isn't about paranoia—it's about preparation. Governments, companies, and organizations are working to improve consumer protections so that people can use crypto securely. And while those measures can make everyday use more secure, no system is completely foolproof. But with these six simple practices, you can help protect your coins, your identity, and your peace of mind: Never share your private key. Your public wallet address is safe to share (it's like your email) but your private key or recovery phrase gives full access to your wallet (it's like your password). Keep it secret, and store it securely offline. Avoid clicking random links. Whether it's a text, tweet, or email, always double-check the source before responding or clicking. Be skeptical of urgency. Scammers rely on pressure tactics. If someone's telling you to act fast or you'll miss out, take a step back. Real opportunities don't rush you. Research before you invest. Don't believe the hype or anonymous tips. Look up the project, the people behind it, and whether it's widely recognized and reputable. Trust your gut—and verify the details. Misspelled names, strange email addresses, or too-good-to-be-true offers are always red flags. Beware of random texts or emails. 'Hey I found your number in my contacts,' a random 'How are you?' from an unknown number or, other out of the blue overtures should always be treated skeptically. General rule of thumb: If it seems too good to be true, it's probably a scam. Take control of your digital destiny Crypto gives people more control, more access, and more opportunity. But that means nothing without trust and safety. You don't have to be a tech wizard or finance pro to use crypto. You just need to be a little 'crypto curious.' When you decide to dip your toe in, practice and a few smart habits—habits you hopefully already use—like double authentication (where your bank, for example, will text you a code). So let's build a safer digital future together. Not by avoiding what's new, but by learning how to navigate it responsibly.

The Sun

12-06-2025

• The Sun

ChatGPT DOWN for hours leaving thousands of users with error messages after mysterious OpenAI outage

CHATGPT users have been hit by random error messages for hours today due to a mysterious outage. Thousands of people complained of problems on the Down Detector website across the globe. The error message reads: "A network error occurred. "Please check your connection and try again. If this issue persists please contact us through our help center at Meanwhile, others have reported a reply that says: "Hmm.. something seems to have gone wrong." Owner OpenAI issued an update on Tuesday afternoon, saying it is "now seeing recovery". But it warned full recovery across all listed services "may take another few hours". "We will continue to provide updates as progress is made," the firm wrote on its service status page. People been complaining on social media about errors all day. X. "Apparently Chatgpt is down globally. I thought my internet was glitching," another commented. A third wrote: "ChatGPT is down….. Which means I actually have to type out my own emails at work." Problems started to pop up at 9am BST. ChatGPT takes swipe at rival Google with surprising new 'shopping' feature - and won't get any ads Is Sora affected? Sora was also affected by Tuesday's outage, with "elevated error rates". Sora is OpenAI's video generation platform, allowing users to create videos out of simple text prompts. The firm says four components are affected. These are: Video generation Video viewing Feed Image generation WHY DO OUTAGES HAPPEN? By Jamie Harris, Assistant Technology and Science Editor at The Sun Outages seem to happen more often these days what with us so dependent on the many apps and digital services on offer. Reasons behind them can vary widely. Usually it's down to an internal error, such as a bungled update that didn't go to plan. These can be minor and reversed within minutes or a couple of hours. But bigger outages can go on for days and cause mayhem, such as the big CrowdStrike tech issue that plunged the world into chaos. Other more serious reasons can be cyber attacks. Bad actors love a DDoS attack, where they bombard a service with so many requests that it struggles to work for anyone. 2